( unodrugTM candidates are developed both...)Hypertension Vaccine CYT006-AngQb Achieves Strong Blood Pressure,Reduction During Important Early Morning Period When Most Adverse,Cardiovascular Events Occur,Health

unodrugTM candidates are developed both in-house and together with Novartis and Pfizer Animal Health. Founded in 1995 as a spin-off from the Swiss Federal Institute of Technology (ETH) in Zurich, the company is located in Schlieren (Zurich). Currently, the company has 130 employees. Cytos Biotechnology AG has been listed on the SWX Swiss Exchange (SWX:CYTN) since October 2002.

References
1 American Journal of Hypertension (2007), 20:587.
2 New England Journal of Medicine (1985), 313:1315.
3 Hypertension (2006), 47:149.
4 Hypertension Research (2006), 29:581.
5 American Journal of Hypertension (2004), 17:347.
6 World Health Organization, Atlas of Heart Disease and Stroke (2004).
7 National Institute for Health and Clinical Excellence (NICE), Centre for Health Services Research, UK; Essential
hypertension: managing adult patients in primary care (August 2004).
Glossary
Ambulatory blood pressure: blood pressure measured continuously during a normally active day; takes numerous automatic readings over a
24-hour period or longer and applies non-invasive ambulatory blood pressure monitoring devices.
Angiotensin II: a molecule of the RAS inducing vasoconstriction of blood vessels and other effects to raise blood pressure.
Antibody: class of blood proteins generated by the immune system to bind and neutralize foreign materials such as bacteria or viruses. Can
also be directed against the body’s own disease-associated molecules (e.g. angiotensin II).
Antihypertensive drugs: a class of drugs used for treatment of high blood pressure.
Asymptomatic: without symptoms.
Booster injection: refers to a vaccination given after a pervious vaccination. Helps to maintain or increase an immune response.
Cardiovascular events: refer to conditions affecting the cardiovascular system, which comprises the heart, the blood vessels, and the cells
and plasma that
'"/>




Page: 1 2 3 4 5 6 7 8 9
Related medicine technology :

1. Speedel Reports Successful SPP635 Phase IIa Trial in Hypertension
2. Prexige Study Shows Significantly Less Impact on Blood Pressure Than Ibuprofen in Osteoarthritis Patients with Controlled Hypertension
3. Lumiracoxib Study Showed Significantly Less Impact on Blood Pressure Than Ibuprofen in Osteoarthritis Patients with Controlled Hypertension
4. Amlodipine and Olmesartan Study Results Released;Late Breaker Presented at American Society of Hypertension Twenty-Second Annual Scientific Meeting (ASH 2007)
5. Gilead Announces Presentation of Long-Term Data for Ambrisentan, a Potential Treatment for Patients With Pulmonary Arterial Hypertension
6. Hypertension Education Foundation Survey Results Announced At American Society For Hypertension Annual Meeting Suggests Improved Control Of High Blood Pressure, But Misconceptions Still Exist
7. New Data Highlights Potential of SPP100 (Tekturna) as Gold Standard Therapy in Treatment of Hypertension
8. Amlodipine and Olmesartan Study Results Released; Late Breaker Presented at American Society of Hypertension Twenty-Second Annual Scientific Meeting (ASH 2007)
9. King Pharmaceuticals Announces Plan to Present Results from Phase III Clinical Trial Evaluating ALTACE as Monotherapy and in Combination with Hydrochlorothiazide at the American Society of Hypertension Annual Meeting
10. Landmark Findings From ECLIPSE Program Show Improved Control of Perioperative Hypertension Reduces Risk of Death In Cardiac Surgery
11. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine